Montvale, NJNCT07913672Now EnrollingIRB Ready

Transplant Failure or Rejection of Bone Marrow (Graft vs Host Disease, GVHD) Clinical Trial in Montvale, NJ

Access cutting-edge transplant failure or rejection of bone marrow (graft vs host disease, gvhd) treatment through this phase 1 clinical trial at a research site in Montvale. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this Montvale location

Preparing your pre-screening questions…

Expert Care in Montvale

Access transplant failure or rejection of bone marrow (graft vs host disease, gvhd) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related transplant failure or rejection of bone marrow (graft vs host disease, gvhd) treatment provided free

Apply for This Montvale Location

Check if you qualify for this transplant failure or rejection of bone marrow (graft vs host disease, gvhd) clinical trial in Montvale, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Montvale

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Montvale site if eligible
  4. 4Begin participation

About This Transplant Failure or Rejection of Bone Marrow (Graft vs Host Disease, GVHD) Study in Montvale

The researchers are doing this study to find out whether the combination of LBP-MARCO (Microbiota Augmentation to Reestablish Commensal Organisms) and ruxolitinib is a safe treatment for people with graft-versus-host disease (GVHD) after receiving a stem cell (allogeneic hematopoietic cell transplantation).

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Ability to swallow capsules
Have undergone allo-HCT from any donor source
Upper GI aGVHD stage 1 and/or lower GI aGVHD stage 1-4. aGVHD affecting other organs (e.g. skin, liver) are allowed
Steroid-refractory, steroid-dependent or intolerant, defined as:
Progressive (i.e., increase in stage of the lower GI tract) after 3 days of treatment with corticosteroids (≥1 mg/kg/day prednisone or IV equivalent), or
Failure to improve (i.e., decrease in stage in the GI tract) after 5 days of corticosteroid treatment (≥1 mg/kg/day prednisone or IV equivalent), or
Incomplete response after \>28 days of corticosteroids, or
Corticosteroid dependent (inability to taper prednisone \<1 mg/kg/day or recurrence of aGVHD activity or flare during steroid taper), or
Corticosteroid intolerance (unacceptable toxicity due to the use of corticosteroids).
Absolute neutrophil count (ANC) ≥0.5 x10\^9/L and platelets \>20,000/mm3. Use of growth factor supplementation and platelet transfusional support is allowed
Ability to start ruxolitinib therapy for aGVHD

Exclusion Criteria

Has received more than one systemic treatment for aGVHD other than corticosteroids +/- CNI or sirolimus prophylaxis or treatment
Active GI bleeding requiring intervention or transfusional support
Toxic megacolon
Active uncontrolled infection requiring systemic antibiotic treatment including persistent bacteremia (controlled infection receiving definitive therapy for 48 hours prior to enrollment are eligible).
Treatment with broad spectrum antibiotic with anaerobic coverage for 48 hours prior to enrollment
Elevated total bilirubin not caused by GVHD or Gilbert's disease of \>5 x upper limit of normal (ULN)
Use of investigational agent within 14 days pre-treatment
Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months
Uncontrolled psychiatric illness
Patients with an active secondary malignancy or prior malignancy requiring systemic therapy within the past 3 years. Exceptions include adequately treated localized non-melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma), as well as localized prostate cancer considered low risk and stable under treatment or surveillance
Female patient who is pregnant or breastfeeding
Known allergy or sensitivity to ruxolitinib and/or MARCO live biotherapeutic

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Montvale?

Yes, this clinical trial (NCT07913672) has an active research site in Montvale, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Transplant Failure or Rejection of Bone Marrow (Graft vs Host Disease, GVHD) Treatment Options in Montvale, NJ

If you're searching for transplant failure or rejection of bone marrow (graft vs host disease, gvhd) treatment options in Montvale, NJ, this clinical trial (NCT07913672) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Montvale research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced transplant failure or rejection of bone marrow (graft vs host disease, gvhd) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all transplant failure or rejection of bone marrow (graft vs host disease, gvhd) clinical trials near you to find additional studies recruiting in your area.

More Atrial Fibrillation Trials in Montvale, NJ

See all atrial fibrillation clinical trials recruiting in Montvale — not just this study.

Browse Atrial Fibrillation Trials in Montvale →

Browse More Trials by Condition

Atrial Fibrillation TrialsHuntingtons Disease TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsFanconi Anemia TrialsAll Conditions →

Ready to Join in Montvale?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Montvale, NJ